Navigation Links
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
Date:3/12/2009

igational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate D-3263, the Company's lead small molecule candidate which targets TRPM8 (a transmembrane cation channel protein), in a Phase 1 dose escalation study in cancer. The application was cleared by the FDA in January 2009.

"This is an exciting time for Dendreon as we await the completion of the final analysis of our IMPACT trial, expected by the end of April. The 20 percent reduction in the risk of death that we saw in the PROVENGE arm at our interim analysis is encouraging to us," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon Corporation. "Our mission is to bring PROVENGE to the many prostate cancer patients seeking treatment alternatives that offer a meaningful survival benefit coupled with a more tolerable safety profile than current options, ultimately translating the success of PROVENGE into a platform of products that could benefit patients with many different types of cancer."

Dendreon expects to have final results from the IMPACT trial in April. The Company expects to host a conference call after the data from the IMPACT trial are known.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 More than ... and about 1 in 3 seniors will die with ... ). These jaw-dropping figures have shocked many Americans into ... hopefully, help prevent these tragic age-related cognitive disorders. Jonathan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Medical Inc. (OTCBB: ONCS), a therapeutic oncology company ... cancers that have unmet medical needs, announced today ... team. Formed earlier this year, OncoSec expects to ... tissue-sparing ElectroOncology therapies before the end of this ...
... IL (May 9, 2011) Research being presented at ... of pediatric patients, including screening for obesity and raising ... in athletes. Additional research emphasizes the need for more ... the benefit of using smaller colonoscopies in young patients. ...
... This discovery will make it possible to improve photoelectrochemical ... to transform sunlight into energy, these cells use sunlight ... water. The process involves using a light-sensitive semi-conducting material ... to fuel the reaction. Although it is not expensive, ...
Cached Biology Technology:OncoSec Announces Leadership Team Appointments 2OncoSec Announces Leadership Team Appointments 3OncoSec Announces Leadership Team Appointments 4New screening techniques, treatments shed light on gastrointestinal disorders in children 2New screening techniques, treatments shed light on gastrointestinal disorders in children 3Harnessing the energy of the Sun: New technique improves artificial photosynthesis 2
(Date:4/17/2014)... per eight hundred births, Down syndrome - or trisomy ... intellectual disability. It results from a chromosomal abnormality where ... chromosome 21 (1% of the human genome). A study ... Department of Genetic Medicine and Development at the University ... Nature , shed light on how the extra chromosome ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
(Date:4/17/2014)... implicated in many serious conditions such as heart disease, ... for drug therapies. Unfortunately, there is still much scientists ... provides fresh and unexpected insight into the structure of ... β-subunit molecules - which are responsible for ,fine-tuning, the ... the most recent edition of the Journal of ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... working in Cameroon and the manager of San Diego ... the prestigious Whitley award. The Whitley award is ... Oscars" because it celebrates the extraordinary achievements of some ... Abwe was selected for the award due to ...
... gout risk, new research reveals that vitamin C, also ... levels to a clinically significant degree in patients with ... with allopurinol, appears to have a weak effect on ... the results published in the American College of Rheumatology ...
... Devonian era some 380 million years ago now ... to remain stable in the face of environmental change, according ... PLOS ONE . Trained to examine species abundance ... stability of Earth,s past ecosystems. The research shows that factors ...
Cached Biology News:Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2Clam fossils divulge secrets of ecologic stability 2
... HyPer is the first fully genetically encoded ... of intracellular hydrogen peroxide (H2O2), one of ... on the basis of yellow fluorescent protein ... coli protein OxyR (OxyR-RD), HyPer demonstrates submicromolar ...
...
Formulation: Phosphate-buffered saline, pH 7.2, containing 0.09% sodium azide....
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
Biology Products: